Skip to main content
Top
Published in: Annals of Hematology 3/2015

01-03-2015 | Original Article

Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)

Authors: A. M. Pfeil, P. Imfeld, R. Pettengell, S. S. Jick, T. D. Szucs, Christoph R. Meier, M. Schwenkglenks

Published in: Annals of Hematology | Issue 3/2015

Login to get access

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in European adults. We aimed to evaluate time trends in CLL incidence and medical resource utilisation of CLL patients in the UK. We conducted a retrospective, observational cohort analysis using the UK Clinical Practice Research Datalink (CPRD) comprising mainly primary care data. We included adult patients with newly diagnosed CLL between January 2000 and June 2012. Descriptive and trend analyses of CLL incidence and medical resource utilisation were performed. A total of 2576 patients with CLL met the eligibility criteria. At diagnosis, the majority of patients (71.7 %) were above 65 years of age. The European age-standardised CLL incidence rate in the CPRD was 6.2/100,000 (95 % confidence interval [CI] 6.0, 6.5/100,000) person-years. There was no statistically significant increase over time. The CLL patients had on average 74.6 general practitioner visits during a median follow-up of 3.3 years. Between 2000 and 2012, the average number of recorded hospitalisations and referrals per year corrected for duration of follow-up significantly (p < 0.001) increased by 8.1 % (95 % CI 6.8 %, 9.3 %) and 16.4 % (95 % CI 15.4 %, 17.3 %), respectively. Referrals and hospitalisations in the second year compared to the first year following the CLL diagnosis significantly decreased. CLL incidence rates in the CPRD were stable over the period from 2000 to 2012. Medical resource utilisation in UK primary care was well documented, but further research is needed to describe secondary and tertiary care medical resource utilisation e.g. chemotherapy administration, which is inadequately captured in the CPRD.
Literature
7.
go back to reference Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174. doi:10.1016/S0140-6736(10)61381-5 PubMedCrossRef Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174. doi:10.​1016/​S0140-6736(10)61381-5 PubMedCrossRef
8.
go back to reference Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. doi:10.1056/NEJMoa1313984 PubMedCrossRef Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. doi:10.​1056/​NEJMoa1313984 PubMedCrossRef
12.
go back to reference Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY (2013) Temporal trends of Barrett’s oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study. Eur J Gastroenterol Hepatol 25(1):15–21. doi:10.1097/MEG.0b013e3283595086 PubMedCrossRef Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY (2013) Temporal trends of Barrett’s oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study. Eur J Gastroenterol Hepatol 25(1):15–21. doi:10.​1097/​MEG.​0b013e3283595086​ PubMedCrossRef
14.
go back to reference Jordan KP, Hayward RA, Blagojevic-Bucknall M, Croft P (2013) Incidence of prostate, breast, lung and colorectal cancer following new consultation for musculoskeletal pain: a cohort study among UK primary care patients. Int J Cancer 133(3):713–720. doi:10.1002/ijc.28055 PubMedCentralPubMedCrossRef Jordan KP, Hayward RA, Blagojevic-Bucknall M, Croft P (2013) Incidence of prostate, breast, lung and colorectal cancer following new consultation for musculoskeletal pain: a cohort study among UK primary care patients. Int J Cancer 133(3):713–720. doi:10.​1002/​ijc.​28055 PubMedCentralPubMedCrossRef
15.
go back to reference Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23(5):686–689PubMedCrossRef Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23(5):686–689PubMedCrossRef
16.
go back to reference Eurostat (2013) Revision of the European standard population—report of Eurostat’s task force. Methodologies & working papers, vol 2013 edition. doi:10.2785/11470 Eurostat (2013) Revision of the European standard population—report of Eurostat’s task force. Methodologies & working papers, vol 2013 edition. doi:10.​2785/​11470
17.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373–383PubMedCrossRef
18.
go back to reference Al-Hashimi MM, Wang X (2013) Comparing the cancer in Ninawa during three periods (1980–1990, 1991–2000, 2001–2010) using Poisson regression. J Res Med Sci 18(12):1026–1039PubMedCentralPubMed Al-Hashimi MM, Wang X (2013) Comparing the cancer in Ninawa during three periods (1980–1990, 1991–2000, 2001–2010) using Poisson regression. J Res Med Sci 18(12):1026–1039PubMedCentralPubMed
19.
go back to reference Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34(2):187–220 Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34(2):187–220
20.
go back to reference Panovska A, Doubek M, Brychtova Y, Mayer J (2010) Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk 10(4):297–300. doi:10.3816/CLML.2010.n.061 PubMedCrossRef Panovska A, Doubek M, Brychtova Y, Mayer J (2010) Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk 10(4):297–300. doi:10.​3816/​CLML.​2010.​n.​061 PubMedCrossRef
21.
go back to reference van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, Nooijen PT, Coebergh JW, Posthuma EF (2012) Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989–2008. Eur J Cancer 48(6):889–895. doi:10.1016/j.ejca.2011.06.053 PubMedCrossRef van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, Nooijen PT, Coebergh JW, Posthuma EF (2012) Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989–2008. Eur J Cancer 48(6):889–895. doi:10.​1016/​j.​ejca.​2011.​06.​053 PubMedCrossRef
22.
go back to reference Cancer Research U (2012) CancerStats—incidence 2009—UK Cancer Research U (2012) CancerStats—incidence 2009—UK
23.
go back to reference Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA (2013) Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 22(2):168–175. doi:10.1002/pds.3374 PubMedCrossRef Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA (2013) Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 22(2):168–175. doi:10.​1002/​pds.​3374 PubMedCrossRef
24.
go back to reference Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52(12):1131–1136PubMedCrossRef Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52(12):1131–1136PubMedCrossRef
25.
go back to reference Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622–626PubMed Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622–626PubMed
26.
go back to reference Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41(3):237–248PubMedCrossRef Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF 3rd (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41(3):237–248PubMedCrossRef
30.
go back to reference Santosh J, Crampton P (2009) Gender differences in general practice utilisation in New Zealand. J Prim Health Care 1(4):261–269PubMed Santosh J, Crampton P (2009) Gender differences in general practice utilisation in New Zealand. J Prim Health Care 1(4):261–269PubMed
Metadata
Title
Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)
Authors
A. M. Pfeil
P. Imfeld
R. Pettengell
S. S. Jick
T. D. Szucs
Christoph R. Meier
M. Schwenkglenks
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2217-7

Other articles of this Issue 3/2015

Annals of Hematology 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.